Dr. Robert Coleman, MD

• Medical Oncology

• Gynecology

*Healthgrades does not verify qualifications for medical specialties. Please verify your provider's specialty and qualifications directly with your provider and applicable medical board.

• University Of Tex Md Anderson Cancer Center

  Fellowship Hospital, 1993

• Northwestern Memorial Hospital

  Residency Hospital, 1991

• Northwestern Memorial Hospital

  Internship Hospital, 1988

• Creighton University

  Medical School, 1987

• Plasma Cell-free DNA in Ovarian Cancer: An Independent Prognostic Biomarker, 2010-04-15

• EphA2 Overexpression is Associated with Lack of Hormone Receptor Expression and Poor Outcome in Endometrial Cancer, 2009-06-15

• The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma, 2020-08-26

• Quality of Life in Patients with Cervical Cancer after Open versus Minimally Invasive Radical Hysterectomy (LACC): a secondary outcome of a multicenter, randomized, open-label, phase 3, non-inferiority trial, 2022-12-08

• Successful use of next generation genomic sequencing (NGS)-directed therapy of clear cell carcinoma of the ovary (CCCO) with trametinib and metformin in a patient with chemotherapy-refractory disease, 2015-08-28

• Correlation of surgeon radiology assessment with laparoscopic disease site scoring in patients with advanced ovarian cancer, 2020-11-05

• Aurora AFunctional Single Nucleotide Polymorphism (SNP) Correlates With Clinical Outcome in Patients With Advanced Solid Tumors Treated With Alisertib, an Investigational Aurora A Kinase Inhibitor, 2017-10-16

• A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer, 2017-02-14

• Dll4 Inhibition plus Aflibercept Markedly Reduces Ovarian Tumor Growth, 2016-03-23

• Olaparib and a-specific PI3K inhibitor alpelisib for patients with epithelial ovarian cancer: a dose-escalation and dose-expansion phase 1b trial, 2019-03-14

• Evaluation of Pegylated Liposomal Doxorubicin Dose on the Adverse Drug Event Profile and Outcomes in Treatment of Recurrent Endometrial Cancer, 2014-01-14

• Data on prior pegylated liposomal doxorubicin (PLD) treatment in recurrent ovarian cancer: Post-hoc data analysis from the phase 3 randomized, open-label study comparing trabectedin and PLD versus PLD alone in patients with recurrent ovarian cancer, 2020-03-20

• Targeting the Tumor Microenvironment in Ovarian Cancer, 2016-02-03

• Therapeutic advances in women's cancers, 2011-01-01

• Immunotherapy targeting folate receptor induces cell death associated with autophagy in ovarian cancer, 2014-11-21

• Rucaparib maintenance treatment for recurrent ovarian carcinoma: the effects of progression-free interval and prior therapies on efficacy and safety in the randomized phase 3 trial ARIEL3, 2021-06-08

• Preclinical and clinical development of siRNA-based therapeutics, 2015-02-07

• Phase II, 2-Stage, 2-Arm, PIK3CA Mutation Stratified Trial of MK-2206 in Recurrent Endometrial Cancer, 2019-12-13

• Targeted PI3K/AKT/mTOR therapy for metastatic carcinomas of the cervix: A phase I clinical experience, 2014-10-29

• Molecular Analysis of Clinically Defined Subsets of High-Grade Serous Ovarian Cancer, 2020-04-14

• Clinical and Biological Significance of Tissue Transglutaminase in Ovarian Carcinoma, 2008-07-15

• Inhibiting Nuclear Phospho-Progesterone Receptor Enhances Antitumor Activity of Onapristone in Uterine Cancer, 2017-12-13

• Maintenance treatment with rucaparib for recurrent ovarian carcinoma in ARIEL3, a randomized phase 3 trial: The effects of best response to last platinum-based regimen and disease at baseline on efficacy and safety, 2021-09-21

• Targeting Src and tubulin in mucinous ovarian carcinoma, 2013-10-07

• Clinical analysis of pathologic complete responders in advanced-stage ovarian cancer, 2022-02-23

• Dual targeting of EphA2 and FAK in ovarian carcinoma, 2009-06-24

• Macrophage depletion through colony stimulating factor 1 receptor pathway blockade overcomes adaptive resistance to anti-VEGF therapy, 2017-08-24

• Improving response to progestin treatment of low-grade endometrial cancer, 2020-05-06

• Moving beyond VEGF for anti-angiogenesis strategiesin Gynecologic cancer, 2013-07-16

• Conservative surgery in early-stage cervical cancer: what percentage of patients may be eligible for conization and lymphadenectomy?, 2010-08-12

• Contemporary use of Bevacizumab in ovarian cancer, 2012-11-29

• Bridging the gap between cytotoxic and biologic therapy with metronomic topotecan and pazopanib in ovarian cancer, 2010-04-06

• PARP Inhibition in the Ovarian Cancer Patient: Current Approvals and Future Directions, 2020-05-23

• PTEN loss is a context-dependent outcome determinant in obese and non-obese endometrioid endometrial cancer patients, 2015-05-16

• PTENexpression as a Predictor of Response to Focal Adhesion Kinase Inhibition in Uterine Cancer, 2015-04-01

• Dual metronomic chemotherapy with nab-paclitaxel and topotecan has potent anti-angiogenic activity in ovarian cancer, 2015-10-29

• Concordance of a laparoscopic scoring algorithm with primary surgery findings in advanced stage ovarian cancer, 2018-10-23

• Is Bilateral Lymphadenectomy For Midline Squamous Carcinoma Of The Vulva Always Necessary? An Analysis From Gynecologic Oncology Group (GOG) 173, 2012-11-29

• Hematogenous metastasis of ovarian cancer: Rethinking mode of spread, 2014-07-14

• Biological roles of the Delta family notch ligand Dll4 in tumor and endothelial cells in ovarian cancer, 2011-07-27

• Erythropoietin Stimulates Tumor GrowthviaEphB4, 2015-10-17

• Transfusion utilization and effect on progression free, overall survival and quality of life in up front treatment of advanced epithelial ovarian cancer: evaluation of the European Organization for Research and Treatment EORTC-55971 cohort, 2023-01-03

• Safety Lead-In of the MEK Inhibitor Trametinib in Combination with GSK2141795, an AKT Inhibitor, in Patients with Recurrent Endometrial Cancer: An NRG Oncology/GOG Study, 2019-10-15

• Targeting Aurora Kinase with MK-0457 Inhibits Ovarian Cancer Growth, 2008-09-01

• GnRH-R targeted lytic peptide sensitizes BRCA wild-type ovarian cancer to PARP inhibition, 2019-03-29

• Investigational Agents in Development for the Treatment of Ovarian Cancer, 2012-06-04

• Tumor core biopsies adequately represent immune microenvironment of high-grade serous carcinoma, 2019-11-26

• A Modified 2 Tier Chemotherapy Response Score (CRS) and Other Histopathologic Features for Predicting Outcomes of Patients with Advanced Extrauterine High-Grade Serous Carcinoma after Neoadjuvant Chemotherapy, 2021-02-09

• Enhanced immunotherapy with LHRH-R targeted lytic peptide in ovarian cancer, 2020-09-17

• Continuous anti-angiogenic therapy after tumor progression in patients with recurrent high-grade epithelial ovarian cancer: phase I trial experience, 2016-04-27

• Utility of18F-FDG PET/CT in follow-up of patients with low-grade serous carcinoma of the ovary, 2014-02-15

• Therapeutic Targeting of ATP7B in Ovarian Carcinoma, 2009-05-26

• Response to pembrolizumab in a heavily treated patient with metastatic ovarian carcinosarcoma, 2018-08-18

• XPO1/CRM1 Inhibition Causes Antitumor Effects by Mitochondrial Accumulation of eIF5A, 2015-04-15

• Platelet-derived growth factor receptor alpha (PDGFRa) targeting and relevant biomarkers in ovarian carcinoma, 2013-10-29

• Prospective pilot trial with combination of propranolol with chemotherapy in patients with epithelial ovarian cancer and evaluation on circulating immune cell gene expression, 2019-07-25

• Critical Questions in Ovarian Cancer Research and Treatment: Report of an AACR Special Conference, 2019-03-05

• A retrospective evaluation of activity of gemcitabine/platinum regimens in the treatment of recurrent ovarian cancer, 2017-11-14

• CT perfusion as an early biomarker of treatment efficacy in advanced ovarian cancer: an ACRIN and GOG study, 2017-02-07

• Targeting Angiogenesis in Gynecologic Cancers, 2012-02-03

• CD63-mediated cloaking of VEGF in small extracellular vesicles contributes to anti-VEGF therapy resistance, 2021-08-17

• Molecular Pathways: Translational and Therapeutic Implications of the Notch Signaling Pathway in Cancer, 2014-11-11

• MOLECULAR BIOMARKERS OF RESIDUAL DISEASE AFTER SURGICAL DEBULKING OF HIGH-GRADE SEROUS OVARIAN CANCER, 2014-04-22

• Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors, 2012-02-28

• Comprehensive epigenetic analysis of Notch pathway in high-grade serous ovarian cancer, 2012-11-28

• Proceedings from the 9th International Conference on Ovarian Cancer, 2011-12-28

• Preclinical mammalian safety studies of EPHARNA (DOPC nanoliposomal EphA2-targeted siRNA), 2017-03-06

• Targeted therapy for intractable cancer on the basis of molecular profiles: An open-label, phase II basket trial (Long March Pathway), 2023-02-23

• New ways to successfully target tumor vasculature in ovarian cancer, 2015-07-31

• MILO/ENGOT-ov11: Binimetinib Versus Physician's Choice Chemotherapy in Recurrent or Persistent Low-Grade Serous Carcinomas of the Ovary, Fallopian Tube, or Primary Peritoneum, 2020-08-21

• Phase II trial of Bevacizumab with Dose-dense Paclitaxel as First-Line Treatment in Patients with Advanced Ovarian Cancer, 2017-08-01

• Converging Evidence for Efficacy from Parallel EphB4 Targeted Approaches in Ovarian Carcinoma, 2010-08-03

• Poly-ADP-ribose Polymerase Inhibitor Use in Ovarian Cancer: Expanding Indications and Novel Combination Strategies, 2019-05-22

• Anti-vascular therapies in ovarian cancer: moving beyond anti-VEGF approaches, 2014-12-30

• NRG1/ERBB3 pathway activation induces acquired resistance to XPO1 inhibitors, 2020-06-04

• A phase I study with an expanded cohort to assess the feasibility of intraperitoneal carboplatin and intravenous paclitaxel in untreated ovarian, fallopian tube, and primary peritoneal carcinoma: A Gynecologic Oncology Group study, 2011-02-01

• Notch3 Pathway Alterations in Ovarian Cancer, 2014-04-17

• A Practical Guide for the Safe Implementation of Early Phase Drug Development and Immunotherapy Program in Gynecologic Oncology Practice, 2018-09-10

• Venous thromboembolism (VTE) rates following the implementation of extended duration prophylaxis for patients undergoing surgery for gynecologic malignancies, 2012-11-28

• Trametinib versus standard of care in patients with recurrent low-grade serous ovarian cancer (GOG 281/LOGS): an international, randomised, open-label, multicentre, phase 2/3 trial, 2022-02-05

• Clinical Significance of Homologous Recombination Deficiency Score Testing in Endometrial Cancer, 2021-02-06

• Combined anti-angiogenic therapy against VEGF and integrin alphaVbeta3in an orthotopic model of ovarian cancer, 2009-12-19

• Rate of para-aortic lymph node micrometastasis in patients with locally advanced cervical cancer, 2010-09-15

• A Phase II study of oral mammalian target of rapamycin (mTOR) inhibitor, everolimus, in patients with recurrent endometrial carcinoma, 2010-08-02

• Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP), 2017-10-23

• BEVACZIUMAB PLUS FOSBRETABULIN IN RECURRENT OVARIAN CANCER: OVERALL SURVIVAL AND EXPLORATORY ANALYSES OF A RANDOMIZED PHASE II NRG ONCOLOGY/GYNECOLOGIC ONCOLOGY GROUP STUDY, 2020-07-26

• Using PARP Inhibitors in the Treatment of Patients with Ovarian Cancer, 2018-11-15

• Biological effects of platelet-derived growth factor receptor a blockade in uterine cancer, 2014-03-14

• Crosstalk between EphA2 and BRaf/CRaf is a Key Determinant of Response to Dasatinib, 2014-01-31

• Gynecologic Oncology Research and Practice: a new journal to meet the needs of a growing field, 2014-09-30

• MEK inhibition overcomes resistance to EphA2-targeted therapy in uterine cancer, 2021-08-11

• Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE), 2020-07-20

• Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial, 2021-05-15

• Antagonism of Tumoral Prolactin Receptor Promotes Autophagy Related Cell Death, 2014-04-03

• Perifosine plus docetaxel in patients with platinum and taxane resistant or refractory high-grade epithelial ovarian cancer, 2012-04-06

• MICROSATELLITE INSTABILITY IN ENDOMETRIAL CANCER: NEW PURPOSE FOR AN OLD TEST, 2019-03-26

• Secondary Somatic Mutations RestoringRAD51CandRAD51DAssociated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma, 2017-06-06

• Predictors of optimal cytoreduction in patients with newly diagnosed advanced-stage epithelial ovarian cancer: time to incorporate laparoscopic assessment into the standard of care, 2015-03-28

• Laparoscopic Surgical Algorithm to Triage the Timing of Tumor Reductive Surgery in Advanced Ovarian Cancer, 2018-06-23

• Advancing Drug Development in Gynecologic Malignancies, 2019-05-24

• Population exposure-efficacy and exposure-safety analyses for rucaparib in patients with recurrent ovarian carcinoma from Study 10 and ARIEL2, 2021-03-19